Inclusion Criteria:  For Participants With Healthy Renal Function  Is in good health based on the opinion of the investigator. Male participants agree to remain abstinent from heterosexual intercourse on a long-term basis or must agree to use contraception as instructed. Female participants must be of nonchildbearing potential.  For Participants With ESRD  With exception of the renal impairment, is in good health based on the opinion of the investigator. Has ESRD maintained on stable regimen of at least 3 times per week HD for at least 3 months prior to the initial administration of the study intervention. Male participants agree to remain abstinent from heterosexual intercourse on a long-term basis or must agree to use contraception as instructed. Female participants must be of nonchildbearing potential.  Exclusion Criteria:  For Participants With Healthy Renal Function  Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Has a history of cancer (malignancy). Is positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV). Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit. Has received any non-live vaccine starting from 14 days prior to study intervention or is scheduled to receive any non-live vaccine through 30 days following study intervention (except coronavirus disease 2019 [COVID-19]).  Participants With ESRD  Has a history of cancer (malignancy). Has required frequent emergent HD (≥3) within a year prior to the initial dose of study intervention. Is positive for HBsAg, hepatitis C antibodies, or HIV. Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit. Has received any non-live vaccine starting from 14 days prior to study intervention or is scheduled to receive any non-live vaccine through 30 days following study intervention (except COVID-19)